^
Association details:
| Biomarker: | HER-2 L755S |
|---|---|
| Cancer: | Salivary Gland Cancer |
| Drug: | Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.
Published date:
05/25/2023
Excerpt:
The (NSCLC) responders in group 1 harbored exon 20 insertions (Y772_A775dup and G778_P780dup) and the SGC, a L755S mutation….T-DM1 has anti-tumor activity across a heavily treated, diverse range of cancer types with HER2 alterations.
DOI:
10.1200/JCO.2023.41.16_suppl.3127
